Growth hormone (GH) use appears to increase the risk of second neoplasms among childhood cancer survivors, but the risk
- PDF / 136,474 Bytes
- 1 Pages / 623.591 x 841.847 pts Page_size
- 83 Downloads / 198 Views
1
■ Growth hormone (GH) use appears to increase the risk of second neoplasms among childhood cancer survivors, but the risk appears to decrease with increasing length of follow-up, according to results of a retrospective, cohort multicentre study. Researchers conducted an additional 32-month follow-up of the Childhood Cancer Survivor Study, which involved 14 108 such patients who had (n = 361) or had not received GH. During the additional follow-up, five and 211 solid second neoplasms were reported among GH recipients (aged 1.5–6.8 years) and nonGH recipients, respectively; meningiomas were the most common neoplasm among GH recipients. Compared with nonGH recipients, GH recipients had a significantly increased risk of developing second neoplasms (adjusted rate ratio [RR] 2.15; 95% CI 1.33, 3.47). According to the researchers, the risk of developing second neoplasms appears to diminish with increasing length of follow-up; the RR before additional follow-up was 3.21. Ergun-Longmire B, et al. Growth hormone treatment and risk of second neoplasms in the childhood cancer survivor. Journal of Clinical Endocrinology 801050512 and Metabolism 91: 3494-3498, No. 9, Sep 2006
0114-9954/10/1124-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
Reactions 21 Oct 2006 No. 1124
Data Loading...
